🚚  Free shipping over $140 — Canadian domestic, no customs Skip to content
FBA

Fat Blaster

Enhanced Lipotropic Blend | L-Carnitine + MIC + B Vitamins + NADH

Limited Research
On this page

We don't stock Fat Blaster yet

Leave your email and we'll notify you if we add it to our research-use-only catalog.

What is Fat Blaster?

Fat Blaster is a compounded lipotropic injection blend — a mix of L-carnitine, methionine-inositol-choline (MIC), B vitamins, and NADH — each ingredient separately studied for a role in liver fat metabolism and cellular energy production. No published research has tested this specific seven-ingredient combination together; its combined effects are inferred from individual-component studies, not demonstrated directly. It's described here strictly as a research reference blend, not a clinical product, and any metabolic research context assumes it's paired with diet and exercise, not used alone.

Key terms:

Fat Blaster is a lipotropic blend (l-carnitine + mic + b vitamins + nadh).

Fat Blaster is a lipotropic injection blend — lipotropic means it works on how the liver handles fat. It combines L-Carnitine, Methionine-Inositol-Choline (MIC), B vitamins (B6 and B12), and NADH. It builds on older MIC injections by adding L-Carnitine, which moves fatty acids into cells, and NADH, which feeds cellular energy production. Formulas differ a lot from vendor to vendor, in both ingredient ratios and strengths. Each ingredient has a documented role in metabolism, though the strength of the clinical evidence varies. No published study has tested this specific combination for weight reduction.

Key research areas

  • Enhanced lipotropic formula combining L-Carnitine for fatty acid transport
  • MIC for liver support
  • B vitamins for energy metabolism
  • NADH for cellular energy
  • Components have varying levels of clinical evidence

Researched dosing

This table reflects dosing volumes and frequencies reported by compounding pharmacies and vendors for this blend, presented as reference information, not personal usage instructions — this specific formulation has no published research trials of its own.

PhaseDoseFrequencyRoute
General metabolic studies1 mL (per vendor formulation)1-2x weeklyIM or SubQ
Body-weight studies1 mL2-3x weeklyIM (clinic) or SubQ (home)
Athletic-performance studies1 mL2-3x weeklyIM or SubQ
Liver and metabolic studies1 mL1-2x weeklyIM or SubQ

Commonly cycled 12 weeks on, 0+ weeks off.

How it works

At the cell level, this blend's ingredients each target a different metabolic step — L-carnitine shuttles fatty acids into cells' energy-producing mitochondria, while the MIC and B-vitamin components support the liver's fat-processing pathways — but no research has studied how they interact together as this specific combination.

L-Carnitine shuttles fatty acids into mitochondria for oxidation. MIC components (methionine, inositol, choline) act as methyl donors and lipotropic agents supporting liver fat metabolism. B6 and B12 support protein and energy metabolism. NADH participates in cellular ATP production. Note: Clinical evidence for this specific combination is absent - effects extrapolated from individual component studies.

Pharmacokinetics

This chart is a general estimate, not ingredient-specific data — because Fat Blaster combines several different compounds with different absorption rates, no single clearance curve has been published for the blend as a whole.

Peak
1 hr
Half-life
4 hrs
Cleared
~20 hrs

Component peptide data estimates

Research applications

This section lists the research areas — fat metabolism, insulin sensitivity, and liver health — that individual ingredients in this blend have been studied for separately; it's a summary of component-level research, not evidence for this specific combination or a claim about outcomes for any person.

Fat Metabolism

Most studied

L-Carnitine shuttles fatty acids into mitochondria. Meta-analysis of 37 RCTs shows modest weight reduction (~1.2 kg) in overweight/obese individuals with exercise. MIC components support hepatic fat metabolism. Choline is essential for VLDL assembly and lipid transport out of the liver. May provide modest metabolic support when combined with diet and exercise. Effects of this specific combination have not been studied.

Insulin Sensitivity

Well studied

Components such as inositol have demonstrated insulin sensitizing effects in clinical studies including PCOS patients.

Liver Health

Early research

MIC components support hepatic fat metabolism and liver lipid processing.

Energy Metabolism

Early research

B6 and B12 support protein and energy metabolism. NADH participates in cellular ATP production.

Dosage reference

Doses used in research
1–2 mL per dose
Frequency in studies
1-3x per week
Handling
Reconstituted solution — research use only; not for administration
Timeline reported in studies
Energy effects (if deficient): days to weeks. Body composition: requires diet and exercise, any effects modest over 4-12 weeks.
Storage
Refrigerate at 2-8°C. Protect from light. Discard if cloudy or discolored.
Cycle length
4-12 weeks typical program length
Break between cycles
Breaks not typically required - can be used ongoing

Interactions

This list shows which other metabolic-research compounds are studied alongside this blend's components, and flags combinations that call for extra caution.

Semaglutide — compatible Tirzepatide — compatible Lipo-C — compatible B-Complex Supplements — compatible MAOIs — compatible Anticoagulants — compatible

Reconstitution & storage

Fat Blaster typically ships pre-mixed and ready to use rather than as a powder to reconstitute — this section covers how a research dose is drawn and handled.

  1. Fat Blaster comes pre-mixed and ready to use - no reconstitution needed
  2. Remove vial from refrigerator 15-30 minutes
  3. Draw prescribed volume (typically 1-2 mL) from multi-dose vial
  4. Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.

Lyophilized: 2-8°C, use within As per manufacturer specification

Reconstituted: 2-8°C, use within Per expiration date on vial; discard if cloudy or discolored

Quality indicators

These are the checks researchers and buyers use to confirm this blend came from a licensed, accredited compounding source with accurate ingredient labeling — since no standardized formula exists across vendors, sourcing verification matters more here than for a single-molecule peptide.

Licensed Compounding Pharmacy - Obtain from accredited compounding pharmacy (look for PCAB accreditation) with proper sterility and quality controls.

Clear Ingredient Labeling - Product should list all 7 ingredients with exact concentrations, lot number, expiration date, and storage requirements.

Healthcare Provider Prescription - Requires prescription from licensed provider who can assess appropriateness and monitor response.

Formulation Variations - No standardized formula exists. 'Fat Blaster' from different vendors may contain different ingredients, ratios, and concentrations.

No Combination Studies - This specific seven-ingredient combination has not been studied. Effects extrapolated from individual component research.

Unregulated Sources - Avoid products from non-licensed sources. FDA does not regulate compounded injections - quality varies significantly.

Exaggerated Claims - Be wary of vendors claiming dramatic weight reduction. Clinical evidence for this combination is limited at best.

What to expect

This timeline reflects what individual-ingredient research suggests may occur at each stage — research context for comparing component studies, not a personal-results promise for this specific blend, which remains unstudied as a combination.

Week 1-2

Possible mild energy improvement, especially if B12 deficient. Injection site reactions possible.

Week 2-4

Gradual effects if any. Do not expect dramatic weight reduction from injections alone - diet and exercise are essential.

Week 4-8

Body composition changes require accompanying caloric deficit and exercise program.

Week 8-12

Modest supportive benefits possible for those following comprehensive weight management.

Safety notes

This section covers handling cautions and regulatory notes for this blend — compounded injections like this are not FDA-regulated for quality or efficacy, and this entry is for research reference only, not medical guidance.

  • Methionine may worsen existing liver disease - contraindicated in advanced hepatic conditions
  • Not a substitute for diet and exercise - weight reduction requires caloric deficit
  • Requires prescription from licensed healthcare provider
  • Use only from reputable compounding pharmacies with proper quality controls
  • FDA does not regulate compounded injections for quality, purity, or efficacy
  • No clinical studies have examined this specific seven-component combination

Regulatory status

  • Not approved by the FDA for any indication.
  • Supplied and described for laboratory research use only — not for human or veterinary use.

Community data

Community Poll

How would you rate your overall experience with this peptide?

1284 votes · Community data

Community Insights

82%reported positive results
68%noticed effects within 2 weeks
91%would recommend to others

Based on data the community reported. Not clinical proof.

References

  1. Human · ~2000mg/day L-Carnitine · Meta-analysis of 37 RCTs

    Meta-analysis found L-carnitine supplementation significantly decreased body weight (-1.21 kg) and fat mass (-2.08 kg), with optimal dose around 2000mg/day. Effects were modest and primarily seen in overweight/obese individuals combining supplementation with lifestyle modifications.

  2. Human · Various inositol doses · Systematic review of 26 RCTs

    Systematic review found inositol treatment induced greater BMI decrease compared to placebo (MD = -0.45). Inositol was noninferior to metformin for metabolic outcomes with better tolerability profile.

  3. Human · 80mg pyridoxine · 8 weeks

    Randomized controlled trial showed 80mg/day B6 supplementation significantly decreased weight (p=0.03), BMI (p=0.023), fat mass (p=0.003), and improved insulin sensitivity compared to baseline in obese/overweight women.